Chen Fei, Qiu Lingdong, Mu Yushu, Sun Shibin, Yuan Yulong, Shang Pan, Ji Bo, Wang Qifei
Department of Gastroenterology, The Second Affiliated Hospital of Shandong First Medical University, Taian, China.
Department of Thoracic Surgery, The Second Affiliated Hospital of Shandong First Medical University, Taian, China.
Front Surg. 2022 Aug 2;9:893372. doi: 10.3389/fsurg.2022.893372. eCollection 2022.
Neoadjuvant anti-programmed death receptor-1 (PD-1) blockade has been reported to improve the prognosis of locally advanced esophageal squamous cell carcinoma (ESCC). This study was aimed to evaluate the efficacy and safety of neoadjuvant camrelizumab plus chemoradiotherapy in locally advanced ESCC.
We retrospectively enrolled ESCC patients who received camrelizumab plus chemoradiotherapy as neoadjuvant therapy before surgery from May 2019 to September 2021.
A total of 38 eligible patients were enrolled. The neoadjuvant treatment was well tolerated with no serious treatment-related adverse events. 36 (94.7%) patients achieved a R0 resection without hospital mortality or any other serious intraoperative complications. The objective response rate (ORR) was 63.2% and the disease control rate (DCR) was 100.0%. The major pathological response (MPR) was 50.0% and the complete pathological response (pCR) was 39.5%. With a median follow-up of 18.5 months, 6 (15.8%) patients had died. The overall survival (OS) and disease-free survival (DFS) at 12 months were 87.6% and 78.7%, respectively. Subgroup analysis demonstrated that patients who got MPR or pCR achieved improved survival, while PD-L1 expression did not reach statistically difference in predicting survival.
Neoadjuvant camrelizumab plus chemoradiotherapy is safe and efficacious in treating patients with locally advanced ESCC.
据报道，新辅助抗程序性死亡受体1（PD-1）阻断可改善局部晚期食管鳞状细胞癌（ESCC）的预后。本研究旨在评估新辅助卡瑞利珠单抗联合放化疗治疗局部晚期ESCC的疗效和安全性。
我们回顾性纳入了2019年5月至2021年9月期间接受卡瑞利珠单抗联合放化疗作为术前新辅助治疗的ESCC患者。
共纳入38例符合条件的患者。新辅助治疗耐受性良好，未发生严重的治疗相关不良事件。36例（94.7%）患者实现了R0切除，无医院死亡或任何其他严重的术中并发症。客观缓解率（ORR）为63.2%，疾病控制率（DCR）为100.0%。主要病理缓解（MPR）为50.0%，完全病理缓解（pCR）为39.5%。中位随访18.5个月，6例（15.8%）患者死亡。12个月时的总生存率（OS）和无病生存率（DFS）分别为87.6%和78.7%。亚组分析表明，获得MPR或pCR的患者生存率提高，而PD-L1表达在预测生存率方面未达到统计学差异。
新辅助卡瑞利珠单抗联合放化疗治疗局部晚期ESCC患者安全有效。
